Latest Regulatory News

Insurance Australia Group (IAG) has entered a strategic alliance with The Royal Automobile Club of Western Australia (RAC), acquiring RAC Insurance and securing a 20-year exclusive distribution agreement. This move significantly boosts IAG's presence in Western Australia and is expected to enhance earnings and operational synergies.

GrainCorp Limited has announced a combined ordinary and special dividend of AUD 0.24 per share, fully franked, reflecting steady returns for shareholders for the first half of 2025.

Tamboran Resources reports strong progress in its Beetaloo Basin pilot project, completing key wells and securing $70 million to fund drilling and infrastructure, aiming for first gas production by mid-2026.

Anson Resources has gained regulatory approval to re-enter a historic well at its Green River Lithium Project, aiming to deepen the reservoir and advance its lithium resource definition. This move sets the stage for a critical feasibility study that could underpin future lithium production.

Tamboran Resources has completed a major stimulation campaign on its Shenandoah South well and raised US$55.4 million to fund further drilling, positioning itself to meet critical gas supply commitments in Australia’s Northern Territory.

Euro Manganese has successfully closed an oversubscribed Security Purchase Plan, raising A$1.5 million to advance its Chvaletice Manganese Project in the Czech Republic. The capital injection will support project development, strategic partnerships, and working capital needs.

Kincora Copper Limited reports a strategic pivot to a project generator model, unlocking over A$110 million in partner funding and advancing multiple copper-gold exploration projects across Australia and Mongolia.

Future Metals NL has announced a partially underwritten entitlement offer aiming to raise approximately AUD 2.64 million to support development of its Eileen Bore Project and working capital needs. The offer opens to eligible shareholders on 15 May 2025 and closes on 30 May 2025.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

MedAdvisor Limited has successfully closed its Share Purchase Plan, raising $2.668 million-exceeding its $2 million target-and plans an upcoming shareholder meeting to approve director share issuances.

PVW Resources reports promising assay results from its Capão Bonito rare earth project and expands exploration efforts across Brazil, bolstered by new metallurgical expertise.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.